Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Cardiovascular Disease and Cancer: Cross-Disease Communication, 10/15/2021 8:00:00 AM - 10/15/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Kathryn J. Moore, PhD
Jean and David Blechman Professor of Cardiology
Director, NYU Cardiovascular Research Center
New York University Langone Health
About our Presenter:
Dr. Kathryn Moore is internationally recognized for her research on the molecular pathogenesis of cardiometabolic diseases, and the roles that non-coding RNAs and dysregulated immune responses play in those settings. Dr. Moore’s contributions to the fields of innate immunity and vascular biology have been recognized by numerous awards, including the NIH’s Outstanding Investigator Award, the AHA’s Distinguished Scientist Award, and election to the National Academy of Sciences USA.
Learning Outcome(s)
Participants will be able to discuss the relationship between cardiovascular disease and cancer, including the mechanisms underlying immune reprogramming after a cardiac event.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Kathryn J. Moore, PhD
Jean and David Blechman Professor of Cardiology
Director, NYU Cardiovascular Research Center
New York University Langone Health
About our Presenter:
Dr. Kathryn Moore is internationally recognized for her research on the molecular pathogenesis of cardiometabolic diseases, and the roles that non-coding RNAs and dysregulated immune responses play in those settings. Dr. Moore’s contributions to the fields of innate immunity and vascular biology have been recognized by numerous awards, including the NIH’s Outstanding Investigator Award, the AHA’s Distinguished Scientist Award, and election to the National Academy of Sciences USA.
Learning Outcome(s)
Participants will be able to discuss the relationship between cardiovascular disease and cancer, including the mechanisms underlying immune reprogramming after a cardiac event.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
